A
Alice S. Mims
Researcher at Ohio State University
Publications - 149
Citations - 3649
Alice S. Mims is an academic researcher from Ohio State University. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 23, co-authored 107 publications receiving 2232 citations. Previous affiliations of Alice S. Mims include The Ohio State University Wexner Medical Center & Medical University of South Carolina.
Papers
More filters
Journal ArticleDOI
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Courtney D. DiNardo,Eytan M. Stein,S. de Botton,Gail J. Roboz,Jessica K. Altman,Alice S. Mims,Ronan T. Swords,Robert H. Collins,Gabriel N. Mannis,Daniel A. Pollyea,William B. Donnellan,Amir T. Fathi,A. Pigneux,Harry P. Erba,Gabrielle T. Prince,Anthony S. Stein,Geoffrey L. Uy,James M. Foran,Elie Traer,Robert K. Stuart,Martha Arellano,James L. Slack,Mikkael A. Sekeres,Christophe Willekens,Sung Choe,Hongfang Wang,Vickie Zhang,Katharine E. Yen,Stephanie M. Kapsalis,Hua Yang,David Dai,Bin Fan,Meredith Goldwasser,Hua Liu,Samuel V. Agresta,Bin Wu,Eyal C. Attar,Martin S. Tallman,Richard Stone,Hagop M. Kantarjian +39 more
TL;DR: In patients with advanced IDH1‐mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment‐related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission.
Journal ArticleDOI
Acute myeloid leukemia, version 3.2019
Martin S. Tallman,Eunice S. Wang,Jessica K. Altman,Frederick R. Appelbaum,Vijaya Raj Bhatt,Dale L. Bixby,Steven Coutre,Marcos de Lima,Amir T. Fathi,Melanie Fiorella,James M. Foran,Aric C. Hall,Meagan A. Jacoby,Jeffrey E. Lancet,Thomas W. LeBlanc,Gabriel N. Mannis,Guido Marcucci,Michael Gary Martin,Alice S. Mims,Margaret R. O'Donnell,Rebecca L. Olin,Deniz Peker,Alexander E. Perl,Daniel A. Pollyea,Keith W. Pratz,Thomas Prebet,Farhad Ravandi,Paul J. Shami,Richard Stone,Stephen A. Strickland,Matthew J. Wieduwilt,Kristina M. Gregory,Lydia J. Hammond,Ndiya Ogba +33 more
TL;DR: This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger and older adult patients.
Journal ArticleDOI
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Gail J. Roboz,Courtney D. DiNardo,Eytan M. Stein,Stéphane de Botton,Alice S. Mims,Gabrielle T. Prince,Jessica K. Altman,Martha Arellano,Will Donnellan,Harry P. Erba,Gabriel N. Mannis,Daniel A. Pollyea,Anthony S. Stein,Geoffrey L. Uy,Justin M. Watts,Amir T. Fathi,Hagop M. Kantarjian,Martin S. Tallman,Sung Choe,David Dai,Bin Fan,Hongfang Wang,Vickie Zhang,Katharine E. Yen,Stephanie M. Kapsalis,Denice Hickman,Hua Liu,Samuel V. Agresta,Bin Wu,Eyal C. Attar,Richard Stone +30 more
TL;DR: Ivosidenib monotherapy was well tolerated and induced durable remissions and transfusion independence in patients with newly diagnosed acute myeloid leukemia (AML).
Journal ArticleDOI
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
Xiaomeng Huang,Sebastian Schwind,Bo Yu,Ramasamy Santhanam,Hongyan Wang,Pia Hoellerbauer,Alice S. Mims,Rebecca B. Klisovic,Alison Walker,Kenneth K. Chan,William Blum,Danilo Perrotti,John C. Byrd,Clara D. Bloomfield,Michael A. Caligiuri,Robert J. Lee,Ramiro Garzon,Natarajan Muthusamy,Ly James Lee,Guido Marcucci +19 more
TL;DR: Tf-NP effectively delivered functional miR-29b, resulting in target downregulation and antileukemic activity and warrants further investigation as a novel therapeutic approach in AML.
Journal ArticleDOI
Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines
Daniel A. Pollyea,Dale L. Bixby,Alexander E. Perl,Vijaya Raj Bhatt,Jessica K. Altman,Frederick R. Appelbaum,Marcos de Lima,Amir T. Fathi,James M. Foran,Ivana Gojo,Aric C. Hall,Meagan A. Jacoby,Jeffrey E. Lancet,Gabriel N. Mannis,Guido Marcucci,Michael Gary Martin,Alice S. Mims,Jadee L. Neff,Reza Nejati,Rebecca L. Olin,Mary Elizabeth Percival,Thomas Prebet,Amanda Przespolewski,Dinesh S. Rao,Farhad Ravandi-Kashani,Paul J. Shami,Richard Stone,Stephen A. Strickland,Kendra Sweet,Pankit Vachhani,Matthew J. Wieduwilt,Kristina M. Gregory,Ndiya Ogba,Martin S. Tallman +33 more
TL;DR: The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making as mentioned in this paper.